General
Preferred name
levamisole
Synonyms
LEVAMISOLE HYDROCHLORIDE ()
(-)-Tetramisole hydrochloride ()
Levamisole HCl ()
Levamisole HCl ()
TETRAMIZOLE HYDROCHLORIDE ()
Levamisole (hydrochloride) ()
(-)-Tetramisole ()
Ergamisol ()
(-)-Levamisole (hydrochloride) (CRM) ()
R 12,564 ()
L-narpenol ()
R-12564 ()
Solaskil ()
Ketrax ()
Ascaridil ()
Levamisoli hydrochloridum ()
Tetramisole hydrochloride, (s)- ()
Spartakon l ()
NSC-177023 ()
R 12654 ()
Levamisol ()
Tetramisole, (s)- ()
TCMDC-125847 ()
(-)-Levamisole ()
P&D ID
PD009109
CAS
16595-80-5
14769-73-4
Tags
available
drug
Approved by
FDA
First approval
1990
Drug indication
acne
Parasitic infection
nephrotic syndrome
Colon cancer
Drug Status
vet_approved
approved
withdrawn
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Levamisole ((-)-Tetramisole) hydrochloride is an anthelmintic and immunomodulator belonging to a class of synthetic imidazothiazole derivatives. Levamisole hydrochloride has antiviral effects against HSV.
INDICATION For adjuvant treatment in combination with fluorouracil after surgical resection in patients with Dukes' stage C colon cancer. Also used to treat malignant melanoma and head/neck cancer.
DESCRIPTION Levamisole is the levorotatory isomer of tetramisole (PubChem CID 3913). This drug was originally used to treat intestinal worm infestations, but also found use in cancer treatment due to its antineoplastic action. This drug is not currently in clinical use in the US or Canada. (GtoPdb)
DESCRIPTION Levamisole ((-)-Levamisole), an anthelmintic agent with immunomodulatory properties. Levamisole acts as a positive allosteric modulator (PAM) for the ¦Á3¦Â2 (EC50=300 ¦ÌM) and ¦Á3¦Â4 (EC50=100 ¦ÌM) subtype of nAChRs. Orally active[1][2].
DESCRIPTION Inhibits multiple mammalian alkaline phosphatases (LOPAC library)
DESCRIPTION Levamisole is levamisole is a nicotinic receptor agonist. It was commonly used for the treatment of parasitic, viral, and bacterial infections. Because of its immunomodulatory effects, this drug has been studied in the treatment of various immune-mediated diseases, with some studies showing positive results. Levamisole has also been used in combination with other drugs for the treatment of various cancers. (Enamine Bioactive Compounds)
DESCRIPTION Levamisole, a thiazole derivative, has been found to be an antibiotic used to against parasitic worm infections and could also have potential activity in anticancer study. (BOC Sciences Bioactive Compounds)
Cell lines
0
Organisms
2
Compound Sets
26
Axon Medchem Screening Library
3242
BOC Sciences Bioactive Compounds
levamisole-cas-14769-73-4-item-59162
Cayman Chemical Bioactives
14874
21321
33972
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1770
CHEMBL1454
ChEMBL Drugs
CHEMBL1770
CHEMBL1454
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00848
DrugBank Approved Drugs
DB00848
DrugCentral
1561
DrugCentral Approved Drugs
1561
DrugMAP
DM5EN79
DrugMAP Approved Drugs
DM5EN79
Enamine Bioactive Compounds
EBC-06511
Enamine BioReference Compounds
Guide to Pharmacology
7210
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1454
Mcule NIBR MoA Box Subset
MCULE-4392506462
MedChem Express Bioactive Compound Library
HY-13666
HY-A0106
Novartis Chemogenetic Library (NIBR MoA Box)
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Levamisole-Hydrochloride(Ergamisol)
Withdrawn 2.0
w51
External IDs
63
Properties
(calculated by RDKit )
Molecular Weight
204.07
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
1
Ring Count
3
Aromatic Ring Count
1
cLogP
2.15
TPSA
15.6
Fraction CSP3
0.36
Chiral centers
1.0
Largest ring
6.0
QED
0.7
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
helminthic nicotinic acetylcholine receptor agonist
Nicotinic Receptor Agonists
immunostimulant
acetylcholine receptor agonist
Target
Nicotinic acetylcholine receptor alpha subunit
ALPPL2, CHRNA3
ALPL
Anthelmintic agent
HSV
Parasite
nAChR
Immunology & Inflammation related
Member status
member
Indication
gastrointestinal parasites
ATC
P02CE01
Toxicity type
hematological
Therapeutic Class
Anticancer Agents
Pathway
Anti-infection
Membrane Transporter/Ion Channel
Neuronal Signaling
Source data